|
ANZMTG 01.14 ABC Trial - A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases |
Brain metastases are a common and serious complication of metastatic melanoma. Up to 50% of patients develop brain metastases during the course of their illness, and approximately 20% of patients have them at first presentation with metastatic disease. This is a Phase 2 study and will look to evaluate the effectiveness of nivolumab and nivolumab combined with ipilimumab in three patient cohorts: cohorts 1 and 3 are melanoma patients with brain metastases that have had no prior localised treatments and no neurological symptoms related to brain metastases, while cohort 2 are melanoma patients with brain metastases who have had a prior failed local therapy or have current neurological symptoms or have leptomeningeal disease
Study Status: Active, not recruiting
Clinical Trials Registry number: ACTRN12614001315606
ClinicalTrials.gov identifier: NCT02374242
Principal Investigator:
Professor Georgina Long
Melanoma Institute Australia (MIA)
Documents (PDF downloads):
|
|
Return to Previous Page
|
|